Equities Analysts Offer Predictions for Accuray Q2 Earnings

Accuray Incorporated (NASDAQ:ARAY) – Equities researchers at Roth Capital dropped their Q2 2025 earnings per share (EPS) estimates for shares of Accuray in a research report issued to clients and investors on Tuesday, November 19th. Roth Capital analyst J. Wittes now expects that the medical equipment provider will earn $0.00 per share for the quarter, down from their prior forecast of $0.01. The consensus estimate for Accuray’s current full-year earnings is $0.01 per share. Roth Capital also issued estimates for Accuray’s Q4 2025 earnings at $0.05 EPS.

Accuray (NASDAQ:ARAY) last released its quarterly earnings results on Wednesday, November 6th. The medical equipment provider reported ($0.04) EPS for the quarter, meeting analysts’ consensus estimates of ($0.04). The business had revenue of $101.55 million during the quarter, compared to analyst estimates of $98.10 million. Accuray had a negative return on equity of 36.93% and a negative net margin of 3.72%. During the same quarter in the prior year, the company posted ($0.03) EPS.

Separately, StockNews.com downgraded Accuray from a “buy” rating to a “hold” rating in a report on Friday, November 15th.

Accuray Trading Up 3.0 %

ARAY opened at $1.89 on Thursday. The business has a 50 day simple moving average of $1.85 and a two-hundred day simple moving average of $1.83. The firm has a market capitalization of $189.57 million, a price-to-earnings ratio of -10.94 and a beta of 1.40. The company has a debt-to-equity ratio of 3.59, a current ratio of 1.63 and a quick ratio of 0.87. Accuray has a one year low of $1.40 and a one year high of $3.05.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in ARAY. Price T Rowe Associates Inc. MD grew its holdings in shares of Accuray by 9.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 73,146 shares of the medical equipment provider’s stock worth $181,000 after acquiring an additional 6,583 shares during the period. Williams & Novak LLC grew its holdings in shares of Accuray by 259.2% during the 2nd quarter. Williams & Novak LLC now owns 96,900 shares of the medical equipment provider’s stock worth $176,000 after acquiring an additional 69,925 shares during the period. Dynamic Advisor Solutions LLC grew its stake in shares of Accuray by 81.6% in the 2nd quarter. Dynamic Advisor Solutions LLC now owns 96,900 shares of the medical equipment provider’s stock worth $176,000 after buying an additional 43,550 shares during the last quarter. Assenagon Asset Management S.A. purchased a new stake in shares of Accuray in the 2nd quarter worth approximately $132,000. Finally, Nisa Investment Advisors LLC grew its stake in shares of Accuray by 253,483.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 15,215 shares of the medical equipment provider’s stock worth $28,000 after buying an additional 15,209 shares during the last quarter. Hedge funds and other institutional investors own 64.08% of the company’s stock.

Accuray Company Profile

Accuray Incorporated designs, develops, manufactures, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the United States, Canada, Latin America, Asia, Australia, New Zealand, Europe, the Middle East, India, Africa, Japan, and China. It offers the CyberKnife platform, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of primary and metastatic tumors outside the brain, including tumors on or near the spine and in the breast, kidney, liver, lung, pancreas, and prostate.